Matinas BioPharma Holdings, Inc.
MTNB
$0.75
-$0.06-7.19%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 70.79% | -216.73% | 80.36% | -97.26% | 25.25% |
| Total Depreciation and Amortization | -9.02% | -4.69% | -48.18% | 1.23% | 1.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -92.94% | 16,961.90% | -99.54% | 374.17% | -0.41% |
| Change in Net Operating Assets | 36.38% | 3.80% | -681.40% | 119.68% | -130.82% |
| Cash from Operations | 27.07% | -0.70% | 42.82% | -0.29% | -12.69% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -94.82% | 428.32% |
| Cash from Investing | -- | -- | -- | -94.82% | 428.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 0.00% | 0.00% | 50.00% | -100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -201.76% | -- | -- | -- |
| Cash from Financing | -96.05% | -1.52% | 164,800.00% | 98.51% | -100.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -173.18% | -10.83% | 88.04% | -149.53% | 93.29% |